Health related quality of life in genital herpes: A pilot comparison of measures

Sexually Transmitted Infections

Volumn 81, Issue 3, 2005, Pages 267-270

  Fisman, David N ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANADA; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; GENITAL HERPES; HEALTH CARE UTILIZATION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION CONTROL; INTERVIEW; MALE; PILOT STUDY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT INFECTION; SEX RATIO; STATISTICAL ANALYSIS; SUPPORT GROUP; VISUAL ANALOG SCALE;

ADULT; AGED; FEMALE; HEALTH STATUS; HERPES GENITALIS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE;

EID: 20644451221     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2004.011619     Document Type: Article

References (28)

1. Corey L, Wald A. Genital herpes. In: Holmes K, Sparling P, Mardh PA, et al, eds. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill, 1999:285-312.
2. Roberts C, Pfister J, Spear S. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003;30:797-800.
3. Fleming D, McQuillan G, Nahmias A, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
4. Fisman DN, Lipsitch M, Hook EW III, et al. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex Transm Dis 2002;29:608-22.
5. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
6. Scoulor A. Using the evidence base on genital herpes: optimising the use of diagnostic tests and information provision. Sex Transm Infect 2002;78:160-5.
7. Wald A, Langenberg A, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. JAMA 2001;285:3100-6.
8. Stanberry L, Spruance S, Cunningham A, et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-61.
9. Laupacis A, Feeney D, Detsky A, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
10. Carney O, Ross E, Ikkos G, et al. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993;69:457-9.
11. Carney O, Ross E, Bunker C, et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med 1994;70:40-5.
12. Patel R, Tyring S, Strand A, et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999;75:398-402.
13. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
14. Fisman DN, Hook EW III, Goldie SJ. Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2. Sex Transm Infect 2003;79:45-52.
15. Neumann P, Goldie S, Weinstein M. Preference-based measures in economic evaluation in health care. Annu Rev Public Health 2000;21:587-611.
16. Doward LC, McKenna SP, Kohlmann T, et al. The international development of the RGHQoL: a quality of life measure for recurrent genital herpes. Qual life Res 19987:143-53.
17. Torrance GW, Feeney D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states. Med Decis Making 2001;21:329-34.
18. Hunink M, Glasziou P. Valuing outcomes. Decision making in health and medicine. 1st ed. Cambridge, UK: Cambridge University Press, 2001:88-128.
19. Torrance GW, Feeny DH, Furlong WJ, et al. Multialtribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996;34:702-22.
20. Landy J, Stein J, Brown MM, et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002;8:CR543-8.
21. Bayoumi AM, Redelmeier DA. Economic methods for measuring the quality of life associated with HIV infection. Qual life Res 1999;8:471-80.
22. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15:369-90.
23. Streiner D, Norman G. Validity. Health measurement scales. 2nd ed. Oxford, UK: Oxford University Press, 1995:144-62.
24. Krahn M, Gofni A. Discounting in the economic evaluation of health care interventions. Med Care 1993;31:403-18.
25. Lenert L, Kaplan RM. Validity and interpretation of preference-based measures of health-related quality of life. Med Care 2000;38:II138-50.
26. Nease RF Jr. Challenges in the validation of preference-based measures of health-related quality of life. Med Care 2000;38:II155-9.
27. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
28. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med 1999;131:194-8.